

GENOCEA BIOSCIENCES, INC.  
Form 8-K  
October 19, 2015

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 19, 2015

GENOCEA BIOSCIENCES, INC.  
(Exact name of registrant as specified in its charter)  
Delaware 001-36289 51-0596811  
(State or other jurisdiction of (Commission File Number) (IRS Employer  
incorporation) Identification No.)

Cambridge Discovery Park  
100 Acorn Park Drive, 5th Floor  
Cambridge, MA 02140  
(Address of principal executive offices) (Zip Code)

(Registrant's telephone number, including area code): (617) 876-8191

Not Applicable  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

Item 7.01. Regulation FD Disclosure.

On October 19, 2015, Genoclea Biosciences, Inc. (the “Company”) issued a press release announcing top-line results from the Company’s Phase 2a trial for its universal vaccine candidate against pneumococcus, GEN-004. A copy of the press release, dated October 19, 2015, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

Item 9.01 Financial Statements and Exhibits.

See Exhibit Index attached hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOCEA BIOSCIENCES, INC.

By: /s/ Jonathan Poole  
Jonathan Poole  
Chief Financial Officer

Date: October 19, 2015

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release issued by Genoceca Biosciences, Inc. on October 19, 2015